Milestone
The relevant milestone is the release of early but strategically important clinical data for spevatamig at ASCO GI 2026. In metastatic pancreatic ductal adenocarcinoma, a disease with poor outcomes and limited room for therapeutic optimism, early data showed median overall survival of 13.2 months for the 2 mg/kg spevatamig plus gemcitabine/nab-paclitaxel regimen, with disease control rate of 93%, objective response rate of 40% and median progression-free survival of 7.3 months in a small first-line cohort.
Why CD47 once looked irresistible
CD47 is an innate immune checkpoint. By engaging SIRPalpha on macrophages, tumor-cell CD47 transmits a "do not eat me" signal that suppresses phagocytosis. The attraction was obvious. If PD-1/PD-L1 blockade unlocked adaptive immunity, CD47 blockade appeared capable of reactivating innate immunity and potentially amplifying downstream antitumor responses. That is why major companies once treated the target as a probable next-wave immuno-oncology platform. The target also fueled a frenzy of transactions, including Gilead's $4.9 billion acquisition of Forty Seven and Pfizer's purchase of Trillium.
Why the first wave failed
The problem was target biology colliding with normal physiology. CD47 is broadly expressed on red blood cells and other normal tissues. As a result, many early antibodies encountered anemia, thrombocytopenia or dosing constraints severe enough to compromise either safety or achievable exposure. Efforts to weaken red-cell binding often improved tolerability but could also dilute efficacy, producing the classic trap of checkpoint engineering: the more one blunts on-target toxicity, the more one risks neutralizing on-target therapeutic value.
Why spevatamig matters mechanistically
Spevatamig attacks that problem through design. It is a natural-IgG bispecific built against CLDN18.2 and CD47, with only one anti-CD47 arm. That architecture is meant to reduce binding to CLDN18.2-negative red blood cells while preserving higher functional avidity on tumor cells expressing the gastric-lineage antigen CLDN18.2. In other words, the molecule is engineered to make CD47 blockade context dependent rather than systemically indiscriminate. That is a more sophisticated solution than simply dialing down affinity across the board.
Clinical evidence and risk-benefit interpretation
In the TWINPEAK phase I program, early results showed not only efficacy signals but also the absence of cytokine release syndrome, dose-limiting toxicity, grade 3 or higher anemia, neutropenia or thrombocytopenia in the study period. For CD47, those safety details are as important as the efficacy readout. A target that repeatedly failed because of hematologic liability cannot re-enter the competitive conversation without a persuasive tolerability story. The small sample size means the data should not be overinterpreted, especially in pancreatic cancer, where early responses do not always mature into durable survival benefit.
Competitive implications
A second layer of evidence also supports rational re-entry into the space: newer molecules such as IMC-002, HCB101, IMD-1005, IMM01 and AK117 are attempting to solve the same problem through different engineering strategies, including selective epitopes, SIRPalpha-Fc formats and masked antibodies activated in the tumor microenvironment. That diversity matters because it suggests the industry has shifted from ideological commitment to CD47 as a hot target toward a more disciplined engineering campaign aimed at target rescue. Capital is also returning, but more selectively, and on terms that reflect technical risk rather than hype.
Outlook
The balanced conclusion is that CD47 is not vindicated yet, but it is no longer the discarded target many assumed after the first wave collapsed. Spevatamig and similar programs imply that the future of CD47 may lie not in broad macrophage checkpoint monotherapy, but in context-restricted formats that combine tumor anchoring, local activation or optimized Fc design. Over the next one to two years, more mature datasets will determine whether this is a genuine comeback or just another temporary rebound. For now, the most important change is intellectual: the field has moved from asking whether CD47 is druggable to asking under what structural conditions it becomes druggable enough.